Drug updated on 4/17/2024
| Dosage Form | Tablet (oral; 50 mg, 100 mg, 150 mg, 200 mg), Injection (intravenous; 200 mg/20 mL), Solution (oral; 10 mg/mL) |
| Drug Class | Functionalized amino acids |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Treatment of partial-onset seizures in patients 1 month of age and older.
- Treatment of adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
Summary
- Lacosamide (Vimpat) is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, as well as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Two systematic reviews/meta-analyses were reviewed which evaluated lacosamide's efficacy and safety profile.
- The first review aimed to evaluate the efficacy and tolerability of lacosamide in patients with Lennox–Gastaut syndrome (LGS), a difficult-to-treat childhood-onset epileptic encephalopathy; it found that on average, 35.2% had >50% reduction, <50% reduction was observed in 27.9%, no change was seen in 7.3%, while worsening seizure frequency occurred among approximately one-third or about 29.4%.
- Adverse events such as somnolence, behavioral abnormalities including irritability/aggressiveness, nausea/vomiting/gastrointestinal discomforts along with tremor/memory problems/weight loss were reported by around a third or precisely about 36% participants but there were no serious adverse events noted during this study involving LGS patients treated with lacosamide.
- The second study compared Vimpat's effectiveness against phenytoin (PHT) for treating status epilepticus; both drugs showed comparable results regarding seizure control - 57.3% achieved through Vimpat versus PHT’s rate at 45.7%. However fewer serious adverse effects were associated with Vimpat than PHT (0.8% vs 5.1%).
- While all-cause mortality rates between these two medications remained similar (p=0.23), survival rates amongst those suffering from moderate-severe disability also did not differ significantly (p=0.37).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vimpat (lacosamide) Prescribing Information. | 2023 | UCB, Inc. Smyrna, GA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and tolerability of lacosamide in lennox–gastaut syndrome: a systematic review and meta-analysis. | 2022 | Journal of Neurosciences in Rural Practice |
| Efficacy of lacosamide and phenytoin in status epilepticus: a systematic review. | 2021 | Acta Neurologica Scandinavica |